We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
- Authors
Hauschild, Axel; Agarwala, Sanjiv S; Trefzer, Uwe; Hogg, David; Robert, Caroline; Hersey, Peter; Eggermont, Alexander; Grabbe, Stephan; Gonzalez, Rene; Gille, Jens; Peschel, Christian; Schadendorf, Dirk; Garbe, Claus; O'Day, Steven; Daud, Adil; White, J Michael; Xia, Chenghua; Patel, Kiran; Kirkwood, John M; Keilholz, Ulrich
- Abstract
This phase III, randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy and safety of sorafenib with carboplatin and paclitaxel (CP) in patients with advanced melanoma who had progressed on a dacarbazine- or temozolomide-containing regimen.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 17, p2823
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.7636